Uncategorized

Australia’s clinical trial advantage gains ground amid U.S. uncertainty

CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies aim to expand that advantage into a broader biotech ecosystem. The question remains whether Australia can support drug development at broader scale.

Australia’s clinical trial advantage gains ground amid U.S. uncertainty Read More »

Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy

As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is pinning hopes on a smooth finish—and possibly, a result in line with Novartis’ spinal muscular atrophy gene therapy Zolgensma.

Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy Read More »

Scroll to Top